The global gene delivery technologies market accounted for USD 4.71 billion in 2023 and is expected to reach USD 23.20 billion by 2034 with a CAGR of 15.61% during the forecast period 2024-2034. The market will rise as a result of factors such as the increasing prevalence of chronic diseases, developments in gene therapy research, high demand for targeted therapies, an increasing emphasis on inherited disorders, rising government support and investment, and technological advancements in delivery methods.
Gene therapy's potential is being increased by ongoing developments in gene delivery methods, including CRISPR-Cas9, non-viral vectors, and viral and non-viral vectors. The development of next-generation gene treatments with superior safety and efficacy profiles is being fueled by advancements in vector design, delivery technologies, and cellular processes. For instance, in May 2023, Kytopen announced the opening of an early access program for its gene delivery technology. The new platform is being designed to create cells that are more effective and efficient.
By mode, the biological segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increased demand for gene therapy treatments and advancements in biological vectors for gene delivery. For instance, in July 2022, Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Company") announced that it and AstraZeneca UK Ltd ("AstraZeneca") had signed a new three-year Master Services & Development Agreement ("the Agreement") to enable AstraZeneca to potentially manufacture the COVID-19 vaccine in the future. Additionally, the chemical and physical segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel non-viral delivery systems and their expanding applications in gene editing and personalized medicine.
By application, the gene therapy segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the rising investment in gene therapy research, expanding clinical applications, and regulatory approvals for gene therapy products. For instance, in January 2022, the leading gene and cell therapy group Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Group") announced that it had inked a new License and Supply Agreement (LSA) with clinical-stage biotechnology company Cabaletta Bio, Inc. located in Philadelphia, Pennsylvania, USA. The agreement focuses on the discovery and development of engineered T-cell therapies for patients. Additionally, the cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in cell engineering, expanding applications in regenerative medicine, and promising clinical outcomes.
By the method, the ex vivo segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increasing adoption of ex vivo gene editing techniques in cell therapy and personalized medicine. For instance, Johnson & Johnson declared in 2023 that they would be expanding their research on gene therapy in partnership with university institutions. Additionally, the in vivo segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel in vivo gene delivery methods, expanding applications in systemic diseases, and advancements in targeted gene editing technologies.
By end-user, the biotechnology and pharmaceutical companies segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increasing investment in gene therapy research and development, expanding product portfolios, and strategic partnerships for commercialization. For instance, in 2023, GSK declared the start of a Phase 1 clinical trial for their beta-thalassemia gene therapy candidate. Additionally, the hospitals and clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for gene therapy treatments, increasing accessibility of advanced medical technologies, and expanding healthcare infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to the establishment of robust healthcare infrastructure, strong research and development activities, and a favorable regulatory environment supporting gene therapy advancements. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare expenditure, increasing adoption of advanced medical technologies, and growing investments in the biotechnology and pharmaceutical sectors. For instance, AstraZeneca stated in 2022 that it was acquiring a gene therapy firm to bolster its pipeline for rare diseases.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Gene therapy's potential is being increased by ongoing developments in gene delivery methods, including CRISPR-Cas9, non-viral vectors, and viral and non-viral vectors. The development of next-generation gene treatments with superior safety and efficacy profiles is being fueled by advancements in vector design, delivery technologies, and cellular processes. For instance, in May 2023, Kytopen announced the opening of an early access program for its gene delivery technology. The new platform is being designed to create cells that are more effective and efficient.
By mode, the biological segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increased demand for gene therapy treatments and advancements in biological vectors for gene delivery. For instance, in July 2022, Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Company") announced that it and AstraZeneca UK Ltd ("AstraZeneca") had signed a new three-year Master Services & Development Agreement ("the Agreement") to enable AstraZeneca to potentially manufacture the COVID-19 vaccine in the future. Additionally, the chemical and physical segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel non-viral delivery systems and their expanding applications in gene editing and personalized medicine.
By application, the gene therapy segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the rising investment in gene therapy research, expanding clinical applications, and regulatory approvals for gene therapy products. For instance, in January 2022, the leading gene and cell therapy group Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Group") announced that it had inked a new License and Supply Agreement (LSA) with clinical-stage biotechnology company Cabaletta Bio, Inc. located in Philadelphia, Pennsylvania, USA. The agreement focuses on the discovery and development of engineered T-cell therapies for patients. Additionally, the cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in cell engineering, expanding applications in regenerative medicine, and promising clinical outcomes.
By the method, the ex vivo segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increasing adoption of ex vivo gene editing techniques in cell therapy and personalized medicine. For instance, Johnson & Johnson declared in 2023 that they would be expanding their research on gene therapy in partnership with university institutions. Additionally, the in vivo segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel in vivo gene delivery methods, expanding applications in systemic diseases, and advancements in targeted gene editing technologies.
By end-user, the biotechnology and pharmaceutical companies segment accounted for the highest revenue-grossing segment in the global gene delivery technologies market in 2023 owing to the increasing investment in gene therapy research and development, expanding product portfolios, and strategic partnerships for commercialization. For instance, in 2023, GSK declared the start of a Phase 1 clinical trial for their beta-thalassemia gene therapy candidate. Additionally, the hospitals and clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for gene therapy treatments, increasing accessibility of advanced medical technologies, and expanding healthcare infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to the establishment of robust healthcare infrastructure, strong research and development activities, and a favorable regulatory environment supporting gene therapy advancements. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare expenditure, increasing adoption of advanced medical technologies, and growing investments in the biotechnology and pharmaceutical sectors. For instance, AstraZeneca stated in 2022 that it was acquiring a gene therapy firm to bolster its pipeline for rare diseases.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Mode, Application, Method, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Gene Delivery Technologies Market Report 2023 - 2034
Gene Delivery Technologies Market Analysis & Forecast by Mode 2023 - 2034 (Revenue USD Bn)
- Biological
- Adenovirus
- Retrovirus
- AAV
- Lentivirus
- Other viruses
- Non-viral
- Chemical
- Physical
Gene Delivery Technologies Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Gene Therapy
- Cell Therapy
- Vaccines
- Research
Gene Delivery Technologies Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Ex vivo
- In vivo
- In vitro
Gene Delivery Technologies Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
Gene Delivery Technologies Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Gene Delivery Technologies Market: Mode Estimates & Trend Analysis
8. Gene Delivery Technologies Market: Application Estimates & Trend Analysis
9. Gene Delivery Technologies Market: Method Estimates & Trend Analysis
10. Gene Delivery Technologies Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Gene Delivery Technologies Market
13. Europe Global Gene Delivery Technologies Market
14. Asia Pacific Global Gene Delivery Technologies Market
15. Latin America Global Gene Delivery Technologies Market
16. MEA Global Gene Delivery Technologies Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- Roche Holding AG
- Sanofi SA
- Merck & Co. Inc.
- GlaxoSmithKline plc
- AstraZeneca plc
- BioNTech SE
- Moderna Inc.
- Editas Medicine
- CRISPR Therapeutics
- bluebird bio Inc.
- Sangamo Therapeutics Inc.
- Intellia Therapeutics Inc..
